About | Free Trial

Last Update


This profile was last updated on .

Is this you? Claim your profile.

Wrong David Heimbrook?

Dr. David Heimbrook C.

Chief Executive Officer, SAIC-Frederick National Laboratory

Cancer Research

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Cancer Research

Background Information

Employment History

President, Leidos Biomedical Research (Formerly SAIC-Frederick)

Leidos Holdings, Inc.

Vice President, Global Head of Discovery Oncology

Roche Diagnostics Corporation


Board Member
The Frederick County Chamber of Commerce

Board Member
The Frederick County Chamber of Commerce

Member of Scientific Advisory Board
Keystone Symposia



molecular biophysics and biochemistry

Yale University

bachelor's degree


Duke University

master's degree

molecular biophysics and biochemistry

Yale University

Web References (85 Total References)

David Heimbrook, Ph.D., CEO, ...

www.worldpreclinicalcongress.com [cached]

David Heimbrook, Ph.D., CEO, SAIC-Frederick National Laboratory for Cancer Research

Board Members| Frederick County Chamber of Commerce | Frederick, MD 21701 - Frederick County Chamber of Commerce

www.frederickchamber.org [cached]

Dr. David Heimbrook Leidos Biomedical Research, Inc.

Dr. David Heimbrook, ...

www.dcmilitary.com [cached]

Dr. David Heimbrook, president of Leidos Biomedical Research, Inc., began this years forum with a brief overview of the Frederick National Laboratory for Cancer Research, the only Federally Funded Research and Development Center in the United States dedicated to biomedical research. He also described past and present research related to the RAS oncogene, which is a protein involved in transmitting signals within human cells.

Mutations or changes in the RAS gene disrupt normal cell function in about thirty-three percent of all human cancers. This mutated gene also lowers or eliminates the effectiveness of cancer therapies targeted at other sites on the cancer cell. For these reasons, according to Heimbrook, scientists are working to expand knowledge of the RAS gene and exploring new ways to develop drugs to counter the contribution of RAS to cancer. He also described the vision of the Advanced Technology Research Facility, located at the Riverside Research Park in Frederick, Maryland, as a hub of RAS expertise.

David Heimbrook, Ph.D., CEO, ...

www.worldpharmacongress.com [cached]

David Heimbrook, Ph.D., CEO, SAIC-Frederick National Laboratory for Cancer Research

Champions Oncology

Break-out Sessions Molecular Med Tri-Con 2011

www.triconference.com [cached]

Moderator: David C. Heimbrook, Ph.D., Global Head, Discovery Oncology, Pharma Research and Early Development, Roche

Similar Profiles

Other People with this Name

Other people with the name Heimbrook

Sandra Heimbrook
Goodwin , Lademan & Associates , Inc.

David Heimbrook
Frederick CREST

David Heimbrook
NIH Institutes

Jessica Heimbrook
Sonoco Limited

Debra Heimbrook
Lucy T. Davis Elementary

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory